clinical-data
(13)
InteropX Sold the Plumbing: How a Five-Person Health-Data Company Made Stale Records Useful
Health plans had APIs, repositories and a stubborn problem: the records still arrived stale, duplicated or trapped in documents. InteropX built the virtual pipe between payers and providers, priced retrieval as low as $1 a chart, and eventually sold the system to Onyx.
InsiteOne Put Medical Images in the Cloud Before the Cloud Had a Name
The Connecticut company bet on off-site medical-image archiving in 1999, survived two giant owners, then returned with a broader plan: make radiology data portable, resilient and useful without forcing hospitals into another proprietary corner.
The Most Expensive Vial in a Clinical Trial Is the One Nobody Can Find
QuartzBio built a business around a stubborn problem in drug development: the sample is physical, the evidence is digital, and the two have a habit of losing track of each other. Its software tries to reconnect the chain before a missing vial or mismatched record becomes a costly trial delay.
Medpace
The Cincinnati CRO built a $2.5 billion business by taking on clinical trials that young biotechs cannot run alone - and by keeping the scientists, software, labs and logistics under one roof.
Astraea
Astraea is a San Francisco startup building an AI-native operating system for clinical trial biometrics. Its agentic platform turns raw study data and a protocol into FDA-ready outputs - SDTM and ADaM datasets, TFLs, and submission packages - compressing work that normally takes months into days while keeping humans in the loop for review and regulatory sign-off. Founded in 2026 by Stanford's Joshua Wang and Sanmay Sarada, the company is part of Y Combinator's Spring 2026 (P26) batch.
Frekil
Frekil is an AI-powered real-world evidence (RWE) platform for life sciences that turns raw clinical data - EHR, claims, and registries - into regulatory-grade evidence in minutes instead of months. Its agentic pipeline runs the full study lifecycle, from literature review and cohort building through statistical analysis plan generation and final reports, while keeping clinical data isolated from AI models. Founded in 2025 by IIT Bombay alumni Nikhil Tiwari and Shivesh Gupta, Frekil is a Y Combinator (X25/P25) company serving pharma, biotech, CROs, and academic researchers.
Predoc
Predoc is a New York-based, clinician-founded startup building an AI-native platform for health information management. It automates the retrieval, cleaning, and structuring of patient medical records - pulling data from digital sources, faxes, and direct provider requests - and turns fragmented, unstructured documents into normalized, actionable data that plugs into existing clinical and research systems. Founded in 2022, the company raised $30M (Series A led by Base10 Partners) and serves oncology groups, research networks, and virtual care providers.
Redox
Redox is a Madison, Wisconsin-based healthcare technology company that runs a cloud network for exchanging clinical and administrative data between health systems, digital health vendors, payers, and life sciences companies. Founded in 2014 by three former Epic Systems engineers, Redox lets a customer connect once to a single API and then reach thousands of healthcare organizations across dozens of electronic health record systems, rather than building and maintaining hundreds of point-to-point integrations. The platform handles standards like HL7v2, CCD, X12, and FHIR, and processes billions of data transactions a year.
Century Health
Century Health is a New York-based health technology company that turns fragmented, messy electronic health record data into clean, structured, analysis-ready real-world evidence. Its AI-powered platform, CHARM (Century Health Abstraction & Retrieval Model), automates the curation, abstraction, and de-identification of clinical data to build disease-specific patient registries for pharmaceutical and life sciences research. Founded in 2023 by Vish Srivastava and Sanjay Hariharan, the company reports 97% accuracy against clinical expert judgment and raised a $5M seed round in 2026 led by Origin Ventures.
PointCross Life Sciences
PointCross Life Sciences is a Foster City, California software and services company that turns the messy data of drug development into FDA-ready submissions. Through its XBIOM platform and eDataValidator, it standardizes nonclinical and clinical study data to CDISC SEND, SDTM and ADaM formats, runs a Hadoop-based data repository for sponsors, and supplies the U.S. FDA itself with the software reviewers use to read nonclinical submissions. The company quietly powers roughly a quarter of all FDA SEND submissions.
Verantos
Verantos is a Menlo Park healthcare technology company that turns messy, fragmented patient records - including the clinical notes most platforms ignore - into research-grade real-world evidence (RWE) at scale. Using AI applied to the complete patient record and a rigorous focus on measured accuracy, completeness, and traceability, Verantos helps pharmaceutical companies, regulators, and health systems generate evidence that can hold up to FDA-grade scrutiny across every therapeutic area.
Tempus AI
Tempus AI is a Chicago-based health technology company that has built one of the world's largest libraries of clinical and molecular data, paired with an AI operating system that helps physicians and researchers make data-driven decisions in oncology, cardiology, radiology, and beyond. Founded in 2015 by Groupon co-founder Eric Lefkofsky after his wife's cancer diagnosis, the company sequences patient genomes, structures messy clinical records, and turns that data into diagnostics and AI tools used across a majority of U.S. academic medical centers. It went public on Nasdaq in June 2024 under the ticker TEM.
Caresyntax
Caresyntax is an AI-powered surgical intelligence platform that turns the operating room into a connected data environment. Its vendor-neutral software captures video, device, and EMR data across more than 4,000 ORs and supports over two million procedures a year, helping hospitals improve outcomes, reduce costs, and make surgery measurably safer.